Leeds, UK, January 21, 2021, - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced its participation in the Microbiome Movement Drug Development Summit - Europe, including the Plenary Session, Microbiome Leaders Industry Review Panel.


  • Plenary Session: European Microbiome Leaders Panel Discussion on Thursday, January 28, 2021 at 8:00am GMT (3:00am ET) with Chief Scientific Officer, Dr. Alex Stevenson, Ph.D.
  • Clinical Trial Design and Evaluating PK/PD Session: MicroRx® and Single Strain Live Biotherapeutics: Proof of Concept Clinical Data and Future Considerations on Thursday, January 28, 2021 at 11:30pm GMT (6:30am ET) with Research Director, Dr. Imke Mulder


About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.


Contact Information:

4D pharma

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations: ir@4dpharmaplc.com


N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Justin McKeegan / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)


Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker


Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com


Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall


BACK TO TOP